Dr Richard Hoglund
Contact information
Research groups
Richard Hoglund
Head of Pharmacometrics
Clinical Pharmacology
Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.
More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.
Recent publications
Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria
Journal article
Ding J. et al, (2026), British Journal of Clinical Pharmacology, 92, 589 - 605
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)
Journal article
Assmus F. et al, (2025), PLOS Neglected Tropical Diseases, 19, e0013522 - e0013522
Pharmacometric and statistical considerations for dose optimization
Journal article
Chotsiri P. et al, (2025), CPT: Pharmacometrics & Systems Pharmacology, 14, 279 - 291
Population pharmacokinetic modelling of primaquine exposures in lactating women and breastfed infants
Journal article
Wattanakul T. et al, (2024), Nature Communications, 15
Medication adherence framework: A population‐based pharmacokinetic approach and its application in antimalarial treatment assessments
Journal article
Ding J. et al, (2024), CPT: Pharmacometrics & Systems Pharmacology, 13, 795 - 811